Neuberger Berman marks down investments in Pine Labs and PharmEasy as tech valuations decline

  • Neuberger Berman has marked down investments in Pine Labs and PharmEasy.
  • This is due to the chill in the consumer Internet investment ecosystem and the subsequent cooling down in startups’ growth in India.
  • The markdowns are being made by US institutional investors of their investments in late-stage companies.


Sign Up for nextbigwhat newsletter

The smartest newsletter, partly written by AI.

Download, the short news app for busy professionals